Aspirin Dilemma: Remodelling the hypothesis from a fertility perspective

Özkan Öztürk
In: Human Reproduction · 2002 · vol. 17(5) , pp. 1146–1148 · doi:10.1093/humrep/17.5.1146 · PMID:11980730 · W2046850923
review OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-12 ⓘ

This paper argues that mismatched aspirin dosage to underlying pathology, particularly in fertility management, explains failed clinical trial outcomes and suggests dose optimization for assisted conception and recurrent miscarriage.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Many clinical trials in obstetrics have failed to demonstrate improved outcomes with low-dose aspirin. This is not entirely surprising as prescribing aspirin for compromised tissue perfusion without insight into underlying pathology inevitably leads to suboptimal outcomes. We argue that a mismatch between the aspirin dose and the underlying pathology of altered tissue perfusion is the key factor to this failure. Based on this groundwork, we address the question of how best to optimize the dose of aspirin for use in fertility management, by providing examples from the assisted conception and recurrent miscarriage settings.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (35)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-06-19T06:35:33.578913+00:00
License: CC0 · commercial use OK